On Friday, TG Therapeutics Inc (NASDAQ: TGTX) opened higher 1.51% from the last session, before settling in for the closing price of $34.55. Price fluctuations for TGTX have ranged from $12.26 to $36.50 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 2506.46%. Company’s average yearly earnings per share was noted -40.74% at the time writing. With a float of $140.42 million, this company’s outstanding shares have now reached $151.42 million.
The extent of productivity of a business whose workforce counts for 264 workers is very important to gauge. In terms of profitability, gross margin is 88.22%, operating margin of -0.19%, and the pretax margin is -5.24%.
TG Therapeutics Inc (TGTX) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of TG Therapeutics Inc is 9.79%, while institutional ownership is 65.33%. The most recent insider transaction that took place on Nov 11 ’24, was worth 152,200. In this transaction Director of this company sold 5,000 shares at a rate of $30.44, taking the stock ownership to the 100,195 shares. Before that another transaction happened on Nov 11 ’24, when Company’s Director sold 25,000 for $30.20, making the entire transaction worth $754,875. This insider now owns 212,479 shares in total.
TG Therapeutics Inc (TGTX) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.1 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.11) by 0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.14 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -40.74% per share during the next fiscal year.
TG Therapeutics Inc (NASDAQ: TGTX) Trading Performance Indicators
Check out the current performance indicators for TG Therapeutics Inc (TGTX). In the past quarter, the stock posted a quick ratio of 3.91. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 20.93.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.11, a number that is poised to hit 0.09 in the next quarter and is forecasted to reach 0.97 in one year’s time.
Technical Analysis of TG Therapeutics Inc (TGTX)
The latest stats from [TG Therapeutics Inc, TGTX] show that its last 5-days average volume of 3.42 million was inferior to 3.7 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 66.78%. Additionally, its Average True Range was 2.27.
During the past 100 days, TG Therapeutics Inc’s (TGTX) raw stochastic average was set at 92.80%, which indicates a significant increase from 88.91% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 90.10% in the past 14 days, which was higher than the 68.66% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $25.61, while its 200-day Moving Average is $19.72. Now, the first resistance to watch is $35.69. This is followed by the second major resistance level at $36.31. The third major resistance level sits at $37.30. If the price goes on to break the first support level at $34.08, it is likely to go to the next support level at $33.09. Assuming the price breaks the second support level, the third support level stands at $32.47.
TG Therapeutics Inc (NASDAQ: TGTX) Key Stats
There are currently 155,665K shares outstanding in the company with a market cap of 5.54 billion. Presently, the company’s annual sales total 233,660 K according to its annual income of 12,670 K. Last quarter, the company’s sales amounted to 83,880 K and its income totaled 3,880 K.
